Earthtimes, June 29, 2007 BRISBANE, Australia -- Progen Pharmaceuticals Limited today announced the establishment of an international clinical advisory board to support the clinical development and commercialization of PI-88 in the treatment of post- resection liver cancer.  The advisory board consists of nine world-renowned thought leaders in the fields of oncology and liver cancer including Professor S. Gail Eckhardt, Professor of Medicine at the University of Colorado Health Sciences Center in Denver, where she also serves as Director of the Developmental Therapeutics and GI Malignancies Programs and Division Head of Medical Oncology. Read more ...  Prior to joining the University of Colorado, Professor Eckhardt served as associate director of clinical research, and as director of the drug development fellowship training at the Institute for Drug Development, Cancer Therapy and Research Center, in San Antonio. She is an associate editor of the Journal of Clinical Oncology, Clinical Cancer Research, and Investigational New Drugs. She has published over 60 manuscripts on her research in GI malignancies. She received her medical degree from the University of Texas Medical Branch in Galveston, Texas.